Marco Davila, Senior Vice President of Translational Medicine at Roswell Park Comprehensive Cancer Center, shared a post on LinkedIn:
“About 6 years ago my lab and the lab of Brian Betts reported the development of a CD83 CAR T cell that treats GVHD and AML.
I’m excited to report that at Roswell Park Comprehensive Cancer Center we have opened the very first clinical trial to evaluate the safety and efficacy of targeting CD83 for our patients with AML.
In fact, we’ve treated the first patient and are enrolling others. When Renier Brentjens recruited me to, it was by telling me I could translate these preclinical ideas into patients quickly. And we did, and in 3 years!! What a cell therapy dream team he has established to make these things possible!!
Patients can only enroll in this trial at Roswell Park but we are negotiating with a couple of our collaborators to open it at their sites too.”
More posts featuring Marco Davila.